Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model

ConditionsMetastasis Predictive Cancer Model

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-75

SponsorFudan University

About this trial

A pre-metastatic target organ/primary lesion fusion radiomics model was developed based on the "soil-seed" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify the performance of the target organ/primary lesion fusion radiomics model in predicting tumor metastasis patterns (brain metastasis in lung cancer, liver metastasis in colorectal cancer, lung metastasis in breast cancer), we designed this prospective observational trial.

Eligibility criteria

Qualifiers

ECOG performance status score 0-2;

Histologically or cytologically confirmed stage III-IV NSCLC;

If the baseline pathology is adenocarcinoma, driver gene testing (at least EGFR/ALK/ROS1/KRAS/MET) should be performed;

Complete imaging data of baseline stage (contrast-enhanced MR For lung cancer, contrast-enhanced MR/CT for colorectal cancer, and chest CT for breast cancer);

Disqualifiers

Patients with indeterminate pathological type;

Patients without baseline imaging data before treatment;

Baseline imaging examination showed that the corresponding target organ had metastasis (lung cancer/colorectal cancer/breast cancer corresponding to brain/liver/lung metastasis);

patients who cannot or refuse to receive regular imaging follow-up;

Trial design

Treatments tested in this trial

Not listed

Trial groups

166 Participants

are grouped into 2 trial groups

Sponsors and collaborators

Fudan University

Lead sponsor

Source ClinicalTrials.gov